KIT
Biomarker
KIT is a receptor tyrosine kinase frequently altered in gastrointestinal stromal tumors. Specific mutations guide the use of targeted kinase inhibitors.
Approvals
1
Indications
1
Therapies
1
Mapped tests
1
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Indication-specific approvals
Approvals where KIT is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Aggressive Systemic Mastocytosis Heme · Mastocytosis |
|
Tumor-agnostic approvals
Approvals defined at the solid tumor level where KIT is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report KIT as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Test
KIT D816V Assay
ARUP Laboratories, Inc.
Method
PCR
Specimen
Bone marrow
Reports KIT as part of its biomarker panel.
1 approvalView test profile →